Vaccines

08 Feb 2022 Immunomic Therapeutics Announces Clinical Trial of ITI-3000 for the Treatment of Merkel Cell Carcinoma
08 Feb 2022 Treos Bio Announces First Patient Dosed in Phase 1b Trial of PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer
04 Feb 2022 Revolo Biotherapeutics Receives MHRA Approval for Two Phase 2 Clinical Trials of ‘1805 in Autoimmune Diseases in the United Kingdom
04 Feb 2022 AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease
03 Feb 2022 EuBiologics: Phase III Clinical Trial IND Approval of EuCorVac-19, COVID-19 Vaccine Candidate, in South Korea
02 Feb 2022 Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA
01 Feb 2022 Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
01 Feb 2022 Valneva Announces Initiation of Adolescent Phase 3 Trial for its Single-Shot Chikungunya Vaccine Candidate
01 Feb 2022 Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
28 Jan 2022 IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
27 Jan 2022 Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant
25 Jan 2022 Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
25 Jan 2022 Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
13 Jan 2022 Gritstone Announces First Patient Enrolled for Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE for First Line (1L) Maintenance Treatment of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)
13 Jan 2022 Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312
07 Jan 2022 Anokion Announces Progress Across Pipeline of Novel Autoimmune Programs
06 Jan 2022 Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
05 Jan 2022 Leiden University Medical Center and Intravacc to Start Clinical Trial with New Intranasal Corona Vaccine
05 Jan 2022 Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19
31 Dec 2021 Johnson & Johnson COVID-19 Vaccine Demonstrates 85 Percent Effectiveness against Hospitalization in South Africa when Omicron was Dominant
28 Dec 2021 Nykode Therapeutics announces first subject dosed with its T cell focused next-generation SARS-CoV-2 vaccine candidate
23 Dec 2021 Vaxzevria significantly boosted antibody levels against Omicron
22 Dec 2021 AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE®AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China
22 Dec 2021 Novavax Announces Initiation of PREVENT-19 COVID-19 Vaccine Phase 3 Trial Booster Study
20 Dec 2021 European Commission Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top